

Rachel J Gibson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4691843/rachel-j-gibson-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111 papers	4,547 citations	42 h-index	64 g-index
116 ext. papers	5,127 ext. citations	4.8 avg, IF	5.37 L-index

#	Paper	IF	Citations
111	Mechanisms of uptake and transport of particulate formulations in the small intestine.. <i>Journal of Controlled Release</i> , 2022 , 343, 584-599	11.7	2
110	Intestinal toll-like receptor 4 knockout alters the functional capacity of the gut microbiome following irinotecan treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 89, 275	3.5	2
109	Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. <i>Integrative Cancer Therapies</i> , 2020 , 19, 1534735420928493	3	14
108	Probiotic Lactobacillus Rhamnosus GG Protects Against P. Gingivalis And F. Nucleatum Gut Dysbiosis. <i>Journal of the International Academy of Periodontology</i> , 2020 , 22, 18-27	0.9	6
107	Cytomorphological Characterization of Individual Metastatic Tumor Cells from Gastrointestinal Cancer Patient Lymph Nodes with Imaging Flow Cytometry. <i>Gastrointestinal Disorders</i> , 2019 , 1, 372-384	0.8	
106	A systematic investigation of the effect of the fluid shear stress on Caco-2 cells towards the optimization of epithelial organ-on-chip models. <i>Biomaterials</i> , 2019 , 225, 119521	15.6	51
105	Mucositis 2019 , 1-17		
104	Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity. <i>Experimental Biology and Medicine</i> , 2019 , 244, 1178-1185	3.7	4
103	Mucositis 2019 , 317-333		
102	Uptake of silica particulate drug carriers in an intestine-on-a-chip: towards a better in vitro model of nanoparticulate carrier and mucus interactions. <i>Biomaterials Science</i> , 2019 , 7, 2410-2420	7.4	21
101	Identifying human and murine M cells in vitro. <i>Experimental Biology and Medicine</i> , 2019 , 244, 554-564	3.7	2
100	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 4011-4022	3.9	26
99	Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis. <i>Annals of Gastroenterology</i> , 2019 , 32, 584-592	2.2	1
98	The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy-induced gastrointestinal toxicity. <i>International Journal of Cancer</i> , 2019 , 144, 2365-2376	7.5	25
97	Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 217-236	3.5	3
96	Optimizing cancer pain management in resource-limited settings. <i>Supportive Care in Cancer</i> , 2019 , 27, 2113-2124	3.9	7
95	Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer. <i>International Journal of Cancer</i> , 2018 , 142, 369-380	7.5	9

94 Mouth **2018**, 1-17

93	Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF β), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. <i>International Journal of Radiation Biology</i> , 2018 , 94, 645-655	2.9	6
92	Probiotic <i>Lactobacillus rhamnosus</i> GG prevents alveolar bone loss in a mouse model of experimental periodontitis. <i>Journal of Clinical Periodontology</i> , 2018 , 45, 204-212	7.7	46
91	Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model. <i>Chemotherapy</i> , 2018 , 63, 284-292	3.2	4
90	Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. <i>Supportive Care in Cancer</i> , 2018 , 26, 3873-3882	3.9	6
89	Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. <i>Gut</i> , 2017 , 66, 1869-1871	19.2	3
88	Mixed effects of caffeic acid phenethyl ester (CAPE) on joint inflammation, bone loss and gastrointestinal inflammation in a murine model of collagen antibody-induced arthritis. <i>Inflammopharmacology</i> , 2017 , 25, 55-68	5.1	9
87	Proteasome inhibitor-induced gastrointestinal toxicity. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 133-137	2.6	11
86	Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. <i>Supportive Care in Cancer</i> , 2017 , 25, 1973-1983	3.9	11
85	Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. <i>International Journal of Cancer</i> , 2017 , 140, 2820-2829	7.5	18
84	Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 431-434	3.5	7
83	Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. <i>Supportive Care in Cancer</i> , 2017 , 25, 391-398	3.9	3
82	Probiotics and Periodontitis - A Literature Review. <i>Journal of the International Academy of Periodontology</i> , 2017 , 19, 42-50	0.9	8
81	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2767-2779	6.1	27
80	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. <i>International Journal of Cancer</i> , 2016 , 139, 2635-2645	7.5	72
79	Radiotherapy-induced gut toxicity: Involvement of matrix metalloproteinases and the intestinal microvasculature. <i>International Journal of Radiation Biology</i> , 2016 , 92, 241-8	2.9	10
78	Chemotherapy-induced gut toxicity and pain: involvement of TLRs. <i>Supportive Care in Cancer</i> , 2016 , 24, 2251-2258	3.9	19
77	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016 , 10, 152-6	2.6	6

76	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 1779-88	3.9	14
75	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1376-86	6.1	72
74	A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. <i>Experimental Biology and Medicine</i> , 2016 , 241, 1386-94	3.7	7
73	Caffeic acid phenethyl ester abrogates bone resorption in a murine calvarial model of polyethylene particle-induced osteolysis. <i>Calcified Tissue International</i> , 2015 , 96, 565-74	3.9	14
72	Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics. <i>Current Oncology Reports</i> , 2015 , 17, 50	6.3	42
71	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. <i>Cancer Treatment Reviews</i> , 2015 , 41, 646-52	14.4	38
70	Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 459-67	3.3	24
69	Beyond conventional pathology: towards preoperative and intraoperative lymph node staging. <i>International Journal of Cancer</i> , 2015 , 136, 743-51	7.5	9
68	Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. <i>Cancer Treatment Reviews</i> , 2015 , 41, 122-8	14.4	31
67	Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity. <i>Cancer Biology and Therapy</i> , 2014 , 15, 236-44	4.6	54
66	TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. <i>International Journal of Cancer</i> , 2014 , 135, 2483-92	7.5	26
65	New pharmacotherapy options for chemotherapy-induced alimentary mucositis. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 347-54	5.4	12
64	Gastrointestinal mucositis: the role of MMP-tight junction interactions in tissue injury. <i>Pathology and Oncology Research</i> , 2014 , 20, 485-91	2.6	20
63	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013 , 21, 3233-41	3.9	89
62	Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. <i>Supportive Care in Cancer</i> , 2013 , 21, 1843-52	3.9	80
61	Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013 , 21, 313-26	3.9	148
60	Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. <i>Experimental Biology and Medicine</i> , 2013 , 238, 1-6	3.7	23
59	Emerging evidence on the pathobiology of mucositis. <i>Supportive Care in Cancer</i> , 2013 , 21, 2075-83	3.9	91

58	Matrix metalloproteinases: do they play a role in mucosal pathology of the oral cavity?. <i>Oral Diseases</i> , 2013 , 19, 347-59	3.5	16
57	Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test. <i>The Journal of Supportive Oncology</i> , 2013 , 11, 61-7		6
56	Swallowing dysfunction in cancer patients. <i>Supportive Care in Cancer</i> , 2012 , 20, 433-43	3.9	101
55	HER2 Targeted Therapy-Induced Gastrointestinal Toxicity: From the Clinical Experience to Possible Molecular Mechanisms 2012 , 69-102		
54	Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. <i>Chemotherapy Research and Practice</i> , 2012 , 2012, 490804	8.04	7 ¹
53	Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 627-35	3.5	3 ¹
52	Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. <i>Chemotherapy</i> , 2011 , 57, 43-53	3.2	11
51	Biomarkers of regimen-related mucosal injury. <i>Cancer Treatment Reviews</i> , 2011 , 37, 487-93	14.4	33
50	Animal models of mucositis: implications for therapy. <i>The Journal of Supportive Oncology</i> , 2011 , 9, 161-8		45
49	Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. <i>International Journal of Experimental Pathology</i> , 2011 , 92, 357-65	2.8	27
48	Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. <i>Oncologist</i> , 2011 , 16, 432-44	5.7	69
47	Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. <i>Experimental Biology and Medicine</i> , 2010 , 235, 1244-56	3.7	5 ¹
46	Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. <i>Toxicology</i> , 2010 , 269, 1-12	4.4	10
45	Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. <i>Radiation Oncology</i> , 2010 , 5, 22	4.2	89
44	Gut microbiome and intestinal mucositis: a new challenge for researchers. <i>Cancer Biology and Therapy</i> , 2009 , 8, 512-3	4.6	7
43	Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. <i>Investigational New Drugs</i> , 2009 , 27, 173-8	4.3	16
42	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 239-51	3.5	124
41	Irinotecan-induced mucositis is associated with changes in intestinal mucins. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 123-32	3.5	57

40	Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1-9	3.5	32
39	Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. <i>International Journal of Experimental Pathology</i> , 2009 , 90, 489-99	2.8	107
38	Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. <i>Experimental Biology and Medicine</i> , 2009 , 234, 430-41	3.7	151
37	Chemotherapy-induced diarrhoea. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 31-5	2.6	49
36	Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. <i>Current Drug Metabolism</i> , 2009 , 10, 79-83	3.5	85
35	HER2 targeted therapies for cancer and the gastrointestinal tract. <i>Current Drug Targets</i> , 2009 , 10, 537-43		16
34	Technological advances in mucositis research: new insights and new issues. <i>Cancer Treatment Reviews</i> , 2008 , 34, 476-82	14.4	12
33	Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1139-45	4.6	120
32	Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1919-25	4.6	114
31	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 33-41	3.5	149
30	Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. <i>International Journal of Cancer</i> , 2007 , 121, 1847-56	7.5	43
29	Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. <i>Oral Oncology</i> , 2007 , 43, 395-401	4.4	119
28	Mucosal injury from targeted anti-cancer therapy. <i>Supportive Care in Cancer</i> , 2007 , 15, 483-90	3.9	49
27	Irinotecan changes gene expression in the small intestine of the rat with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 337-48	3.5	34
26	VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. <i>Cancer Biology and Therapy</i> , 2007 , 6, 1449-54	4.6	117
25	Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. <i>Cancer Biology and Therapy</i> , 2007 , 6, 541-7	4.6	13
24	A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2319-27	6.1	50
23	Establishment of a single-dose irinotecan model of gastrointestinal mucositis. <i>Chemotherapy</i> , 2007 , 53, 360-9	3.2	52

22	Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. <i>Anti-Cancer Drugs</i> , 2007 , 18, 197-210	2.4	20
21	Severe mucositis: how can nutrition help?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2007 , 10, 627-31	3.8	20
20	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. <i>Cancer Treatment Reviews</i> , 2007 , 33, 448-60	14.4	200
19	Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. <i>Experimental Biology and Medicine</i> , 2007 , 232, 96-106	3.7	38
18	Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. <i>The Journal of Supportive Oncology</i> , 2007 , 5, 259-67		39
17	Sucrose breath testing and intestinal mucositis. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1196-8	4.6	5
16	The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem!. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1282-4	4.6	10
15	Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2. <i>Cancer Treatment Reviews</i> , 2006 , 32, 645-51	14.4	35
14	Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006 , 2, 39-49	1.9	20
13	Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. <i>Supportive Care in Cancer</i> , 2006 , 14, 713-31	3.9	96
12	Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. <i>Supportive Care in Cancer</i> , 2006 , 14, 890-900	3.9	147
11	Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. <i>Pathology</i> , 2005 , 37, 56-62	1.6	62
10	Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 1295-303	4	77
9	Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. <i>International Journal of Cancer</i> , 2005 , 116, 464-70	7.5	67
8	Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. <i>Clinical and Experimental Medicine</i> , 2005 , 4, 188-95	4.9	42
7	Gastrointestinal mucositis. <i>Seminars in Oncology Nursing</i> , 2004 , 20, 38-47	3.7	66
6	Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 1095-100	4	132
5	The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 53-8	3.5	77

4	Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 2751-7	4	74
3	Relationship between Animal Models and Clinical Research: Using Mucositis as a Practical Example	81-108	
2	Use of Project Teams in Preclinical Development	1	
1	Relationship between Animal Models and Clinical Research: Using Mucositis As A Practical Example	1	